However, in consideration of the two unique cancer cases (PDAC, HCC) among all other types of cancer reviewed in the subsection of “DDX5 in general DNA damage repair and cancer malignancy”, the downregulation of DDX5 during liver to lipid-mediated disease progression could be the negative feedback against the disease (i.e., cells trying to slow disease development) and this would need further investigation, from which we may obtain unexpected findings to unify all observations. This evidence concerns the gene DDX5 and hepatocellular carcinoma.